The Existential Buyout: Why Healthcare Incumbents Are Rushing AI M&A

BOSTON, MA – November 04, 2026 — The architecture of the global healthcare system is undergoing a fundamental rewiring. For the past decade, the digitization of medicine was defined by the slow, painful rollout of electronic health records and traditional Software-as-a-Service (SaaS) platforms. Today, that static infrastructure is being aggressively overwritten by artificial intelligence. It is a transition that is leaving legacy medical technology and pharmaceutical conglomerates facing a stark reality: their internal research and development engines are simply too slow to keep up.

Sensing this systemic shift, Outcome Capital, a specialized life sciences and healthcare advisory and investment banking firm, announced today the appointment of Dr. David Feygin as Managing Director and Head of Digital Health, SaaS and AI. Operating in a full-time leadership capacity, Dr. Feygin is tasked with expanding the firm’s strategic advisory capabilities as artificial intelligence creates unprecedented avenues for value creation—and destruction—across the healthcare ecosystem.

The appointment is more than a routine executive reshuffle. It serves as a bellwether for a broader transformation in healthcare investment banking, where the convergence of clinical science, complex data architecture, and high-stakes corporate finance requires a new breed of dealmaker. As the healthcare AI market barrels toward a projected $110 billion valuation by the end of the decade, the industry is transitioning from a period of venture-backed experimentation into an era of ruthless, existential consolidation.

The Existential Buyout: When Organic Growth Fails

For traditional MedTech and healthcare conglomerates, the emergence of clinical and operational AI is not just a new product category; it is a threat to their core business models. Historically, these incumbents relied on massive distribution networks and deep regulatory moats to maintain market dominance. Software was viewed as an ancillary feature to hardware or pharmaceutical interventions.

That paradigm has collapsed. As AI shifts from an experimental novelty to a foundational operational requirement, legacy companies are finding that they cannot hire data scientists or train foundational models fast enough to compete with agile, AI-native startups.

“Organic development alone can't keep pace with AI. As startups prove their models, enterprise acquisitions will accelerate, and Health AI companies that show even early commercial scalability will command unprecedented multiples, because AI has become existential for every incumbent,” Dr. Feygin noted in the firm's announcement.

This dynamic is triggering a massive acceleration in "build, buy, or partner" evaluations inside corporate boardrooms. Following a slight dip in overall digital health M&A in 2024, the market rebounded violently in 2025, with annual funding for U.S. digital health startups surging 35% to $14.2 billion. Much of this capital was concentrated in high-conviction AI bets. Now, as these well-capitalized startups reach commercial maturity, the acquisition pipeline is primed.

"We used to have a five-year window to observe an emerging technology before we had to make a move," noted one corporate development executive at a top-tier medical device manufacturer. "With agentic AI, if we wait five months, the startup has either been acquired by a competitor or their valuation has grown completely out of our reach. We are being forced to acquire capabilities defensively."

Beyond Traditional SaaS: The Agentic Valuation Premium

The urgency driving this M&A wave is compounded by a structural shift in how healthcare software is valued. For years, digital health companies modeled themselves after enterprise SaaS giants, charging per-seat licensing fees for static workflow tools. However, advances in agentic AI—systems capable of autonomous reasoning, decision-making, and executing complex, multi-step workflows—are rendering the per-seat model obsolete.

Agentic AI does not simply assist a human worker; it completes the task. Whether it is autonomous medical coding, predictive patient monitoring, or generative clinical documentation, these systems are outcome-driven. Because they directly reduce labor costs and improve clinical throughput, they command entirely different financial multiples.

Outcome Capital has been closely tracking this divergence in the market. In 2024 and 2025, AI-native biotechs and healthtech firms consistently secured median valuations nearly double those of their non-AI peers. Companies focused on automating clinical workflows, such as those tackling medical documentation, have recently achieved multi-billion-dollar valuations based on their ability to scale trusted algorithms across entire hospital networks.

“AI represents a once-in-a-generation shift in how value is created and captured across the industry. One of the most important questions facing healthcare companies today is whether to build, buy or partner to capitalize on the next-generation of digital health platforms,” said Dr. Feygin. “Outcome Capital brings these perspectives together to help clients make informed decisions in an emerging AI-driven economy.”

For investment banks advising on these transactions, the challenge is accurately pricing this outcome-driven model. Traditional discounted cash flow analyses and SaaS revenue multiples fall apart when evaluating an algorithm that can autonomously scale to handle the administrative workload of a thousand nurses overnight.

The Rise of the Operator-Banker

This complexity explains why boutique investment banks like Outcome Capital are increasingly bypassing career financiers in favor of seasoned clinical and technological operators. Separating genuine, scalable artificial intelligence from marketing hype requires deep domain expertise. Acquirers are terrified of buying a "black box" algorithm that fails to integrate into existing hospital IT infrastructure or, worse, violates stringent healthcare data regulations.

Dr. Feygin’s background perfectly encapsulates this new "operator-banker" archetype. He holds a PhD in Mechanical Engineering from UC Berkeley and an MBA from Harvard Business School. Before pivoting to advisory, he was the Chief Digital Health & Data Officer at Boston Scientific, where he led enterprise digital, data, and analytics efforts. Prior to that, he spent years at Becton Dickinson driving strategic innovation, playing a role in the company's massive $12 billion acquisition of CareFusion.

Beyond corporate leadership, Dr. Feygin has spent time in the entrepreneurial trenches as the CEO and Co-Founder of SHAKEIQ, an AI startup transforming how medical technology innovators engage providers, and EnPraxis, a platform for governed cognitive operations.

“I've worked on both sides of this, leading digital and AI strategy inside a global MedTech leader and building AI companies from the ground up," Dr. Feygin stated. "At Outcome, I'll use that experience to help founders show buyers that their business model can scale and their AI can be trusted, and to help acquirers tell real innovation apart from hype, so that AI innovation turns into transactions that create lasting value.”

This dual perspective is becoming a prerequisite for orchestrating successful healthcare transactions. The regulatory landscape for medical AI is notoriously difficult to navigate, and algorithms that perform perfectly in isolated training environments frequently break down when exposed to the chaotic, unstructured data of real-world clinical settings.

“AI and digital health are converging rapidly, fundamentally changing the competitive landscape for companies. This change requires a deep understanding of emerging trends, clinical and regulatory dynamics, and investor and enterprise priorities,” explained Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital. “With David leading this practice, we're better positioned to help clients anticipate market changes for strategic opportunities.”

As the healthcare sector braces for a historic wave of consolidation, the firms that successfully navigate this transition will be those that understand the underlying code as well as they understand the balance sheet. With the appointment of Dr. Feygin, Outcome Capital is betting that the future of healthcare investment banking belongs to those who have actually built the systems they are now being hired to sell.